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Abstract
Background: Respiratory rate (RR) is the most sensitive physiological observation to predict clinical deterioration on hospital
wards, and poor clinical monitoring has been highlighted as a primary contributor to avoidable mortality. Patients in intensive
care have their RR monitored continuously, but this equipment is rarely available on general hospital wards.
Objective: The primary objective is to assess the accuracy of the RespiraSense device in comparison with other methods
currently used in clinical practice. The secondary objective is to assess the accuracy of the RespiraSense device in participants
in different positions and when reading aloud.
Methods: A single-center, prospective observational study will investigate the agreement of the RespiraSense device as compared
with other device measurements (capnography, electrocardiogram) and the current standard measurement of RR (manual counting
by a trained health care professional). The different methods will be employed concurrently on the same participant as part of a
single study visit.
Results: Recruitment to this study has not yet started as funding decisions are still pending. Therefore, results are not available
at this stage. It is anticipated that the data required could be collected within 2 months of first recruitment to the study and data
analysis completed within 6 months of the study start date.
Conclusions: The Evaluation of Agreement of Breathing Rates Measured by a Novel Device, Manual Counting, and Other
Techniques Used in Clinical Practice (VENTILATE) study will provide further validation of the use of the RespiraSense device
in subjects with abnormal respiratory rates.
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Introduction
Background
Patients admitted to acute hospitals undergo regular monitoring
of their vital observations as a key component of their care. In
2007, the National Institute for Health and Clinical Excellence
(NICE) produced recommendations for the measurement and
recording of physiological observations [1] in response to
several multicenter studies that revealed a significant lack of
documentation of these observations.
Since the 1990s it has been recognized that the respiratory rate
(RR) is the most sensitive physiological observation to predict
cardiac arrest on hospital wards [2]. Despite this understanding,
monitoring of the RR is demonstrated to be the most common
vital sign to be inaccurately measured or recorded [3-5]. More
recently, poor clinical monitoring has been highlighted as a
primary contributor to avoidable mortality in English hospitals,
implicated in 31% of preventable deaths [6].
The most commonly taught and used technique for measuring
the RR is manually counting the number of breaths per minute
a patient takes. A manual RR should be measured for a period
of at least 1 minute, and the normal range for adults (aged 18
years and above) is 12 to 20 breaths per minute [7]. However,
a recent cross-sectional study identified significant inaccuracies
in the measurement of the RR among UK doctors and
highlighted it as an important aspect of clinical care that is
currently being poorly performed [8]. Manual counting among
other clinical staff in routine practice has also been observed to
be inaccurate, possibly due to the approach of counting breaths
for 15 seconds and then multiplying by 4 to get breaths per
minute, thus introducing error. This leads to somewhat of a
self-fulfilling prophecy where expected inaccuracies in the
measurement of the RR reduce the confidence of clinical staff
at all levels in the usefulness of a reportedly abnormal RR [9].
Patients in intensive care are able to have their RR monitored
accurately and continuously by capnography [10]. This type of
monitoring can be invasive as it usually requires endotracheal
intubation, and patients in other hospital areas do not usually
need such an invasive intervention nor is the nursing staff likely
to have access to such equipment. However, a systematic review
has identified that the existing evidence for routine continuous
noninvasive respiratory monitoring on general hospital wards
is still inconclusive, and studies are lacking in methodological
quality [11]. It recommends that future research should focus
on technology explicitly suitable for general hospital wards and
explore tailored alarm and treatment algorithms. The first step
in such research is to explore the level of agreement between
any new technology and current methods of establishing RR.
The significance of the accuracy of the RR recording cannot be
overestimated [8,9]; it plays an important role in many clinical
assessment systems, including the assessment of acute asthma
and systemic inflammatory response syndrome and in the
calculation of early warning scores [8]. This score alerts staff
to any clinical deterioration and depending on the severity of
the score, prompts a review from nursing or clinical staff.
The adoption of these scores has subsequently led to the
development of multiple track and trigger information
technology systems to allow early detection of patient
deterioration [1]. Current systems rely on the manual assessment
of the RR by a health care provider (HCP) and entry of data
onto a live database in order for it to be processed. At
Portsmouth Hospitals NHS Trust (PHT), the Vitalpac (System
C) mobile clinical software system is used to record observations
and calculates an early warning score (National Early Warning
Score [NEWS]) depending on the degree of deviation from the
normal range, with the total score proportionate to the overall
level of risk (Table 1).
The RespiraSense device (PMD Solutions Ltd) was developed
to improve the detection of changes in the RR in order to alert
staff to out-of-range values that may be clinically significant.
In a 48-patient investigation, data were collected to evaluate
the difference in RR measurements between the developed
RespiraSense device, electrocardiogram (ECG), and direct
nursing observations [12]. A clinically relevant agreement
between all RR measurements by the 3 different methods was
demonstrated. However, few abnormal values were recorded
in this investigation, and further research is required to ensure
that the device works well to accurately measure the RR at
values both higher and lower than the normal range.
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Table 1. Escalation protocol for the deteriorating patient [8].
ScoreVital sign
3210123
≥131 Unrecordable due to
patient condition
111-13091-11051-9041-50—≤40Pulse
Unrecordable due to patient
condition
≥3938.1-3936.1-3835.1-36—≤35Temperature (°C)
≥220 Unrecordable due to
patient condition
——111-219101-11091-100≤90BPa systolic (mm Hg)
≥25 or Unrecordable due to
patient condition
21-24—12-209-11—≤8Respiratory rate (bpm)
Voice pain unresponsivec——Alert———AVPUb
Unrecordable due to patient
condition
——≥96 or Unrecordable because
patient refused, equipment
unavailable, other reason
94-9592-93≤91SaO2d
—Any supple-
mental O2e
—Air———Inspired O2
aBP: blood pressure.
bAVPU: alert, verbal, pain, unresponsive.
cIf AVPU is V or C due to patient sedation, it will be charted as S and score 0 rather than 3.
dSaO2: oxygen saturation.
eNote that “any supplemental O2” applies to any supplemental oxygen the patient is receiving. It does not apply to patients who are on masks through
which only air is being supplied (air delivery possible through tracheostomy, bilevel positive airway pressure or continuous positive airway pressure,
for example).
Objectives
This research aims to assess the accuracy of the RespiraSense
device in comparison with other methods (capnography, ECG)
and standard care (manual RR monitoring) in healthy
participants across a range of predetermined RRs. The
information from this study will contribute to the evidence base
on RespiraSense to enable its use in clinical practice.
This investigation will supplement the following research that
has been conducted in demonstrating the efficacy and/or
accuracy of RespiraSense in a clinical setting:
• “Evaluation of a continuous monitoring device in capturing
respiratory rate compared to industry standard and gold
standard” (Bangor, study reference PMD-CS-007)
• “Can respiratory rate predict the risk of deterioration of
septic patients?” (Denmark, study reference PMD-CS-006ii)
• “A quality assurance study of respiratory rate measurements
on obese patients with a novel monitoring technology”
(Portsmouth, study reference PMD-CS-011)
The primary objective is to assess the agreement of the
RespiraSense device with alternative methods of RR counting
in healthy participants. Secondary objectives are to (1) explore
whether the position of the participant has any effect on the
agreement between the RespiraSense device readings and
alternative methods of RR counting, (2) explore whether the
agreement of the RespiraSense device and alternative RR
methods alters when a participant is reading aloud, and (3)
establish agreement between manual counting of the RR and
retrospective adjudication of video. The exploratory objective
is to record any dermatological effects of the device.
Methods
Patient Selection
Selection criteria for the study are shown in Textbox 1.
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Textbox 1. Selection criteria.
Inclusion
• Male or female
• Aged ≥18 to 60 years
• Able and willing to provide written informed consent
Exclusion
• Any significant medical condition that may be worsened by the effect of slow or fast breathing
• Significant hearing impairment
• Skin unsuitable for device following assessment of skin fragility
• Unable to access left side of abdominal wall to attach device
• Neuromuscular disease and irregular chest wall movements
• Allergy to medical-grade skin adhesive
• Pregnant women during second and third trimester
Recruitment
Participants will be recruited from the population of staff and
students currently working or on placement at PHT. Flyers
advertising the study will be posted in communal areas where
these groups are likely to congregate (eg, doctors’ mess, ward
break rooms). These flyers will contain contact details for the
research team and advise those who are interested in taking part
in the study to contact the research team.
Potential participants will be contacted by telephone and sent
a participant information sheet (PIS). Participants who then
wish to take part in the study will be invited to a screening visit.
During this visit, the study will be explained, all questions
answered, and participant will be screened against the inclusion
and exclusion criteria. Additionally, the participant will be asked
to breathe at a rate of 30 breaths per minute to assess their
comfort while performing a study procedure. Those who are
unable to maintain a rate of 30 breaths per minute for 2 minutes
will be excluded from the study. Following this screening visit,
the participant will be followed up with a telephone call to
confirm that they are still willing to take part in the study.
Study Design
The study is a single-center, prospective observational study to
investigate the agreement of the RespiraSense device compared
with (1) other device measurements (capnography, ECG) and
(2) the current standard measurement of RR (manual counting
by a trained HCP). The different methods will be employed
concurrently on the same participant as part of a single study
visit.
Once participants have provided consent, the following baseline
data will be collected:
• Demographics (age, sex)
• Height, weight (to calculate body mass index)
• Skin assessment at RespiraSense device attachment site
(color, texture, uniformity of appearance, integrity). It will
also be confirmed that the skin has no discoloration or rash,
epidermal loss, blistering, edema, tears, maceration or
folliculitis
• Oxygen saturation and pulse oximetry
Participants will be asked to wear a hospital gown and be
positioned on an examination couch in the simulation suite. The
RespiraSense device, a nasal cannula, and an ECG will be
attached and a video recorder positioned to ensure the viewers
of the video experience the same image as the HCP performing
manual RR monitoring.
A computer-based metronome will be used to produce a
repetitive tone at a set rate, which is played to each participant
via headphones. The metronome has been produced for the
study by the study sponsor team using Microsoft Visual Basic.
The metronome rates will be generated using a random number
generator program, and the order of the different rates will vary
with each participant to ensure the rates are random. The
participants will be asked to begin to inspire when each tone is
heard and will be given a 20-second warm-up period during
which time they will regulate their breathing pattern to match
the rate of the tone they hear. Each participant will be asked to
breathe at one value from each of the following categories for
2 minutes:
• ≤8 breaths per minute
• 9 to 11 breaths per minute
• 12 to 20 breaths per minute
• 21 to 24 breaths per minute
• 25 to 29 breaths per minute
• 30 to 35 breaths per minute
One rate will be randomly generated from within each of the 6
categories. Examples of potential sets are shown in Table 2.
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Table 2. Examples of possible sets of metronome rates to be used.
Sixth rateFifth rateFourth rateThird rateSecond rateFirst rateParticipant
32281723106Participant A
2631229145Participant B
27332113711Participant C
Each participant will be studied in the normal position (ie, sitting
at 45 degrees on a couch) for 6 different metronome rates. They
will then be studied in one of the three following additional
positions for an additional 4 metronome rates: supine (flat on
their back), left lateral decubitus (recovery) position, or sitting
at 90 degrees (chair position).
Each metronome rate will be maintained for 2 minutes with 2
to 5 minutes in between for transition (or longer if required by
the participant to return to normal breathing rates). A full process
flow of the requirements of each participant is shown in Figure
1.
Figure 1. Participant process flow diagram.
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The research team will consist of 3 members; the layout of the
study room is shown in Figure 2. Research member 1 will
indicate to the participant when a new metronome rate starts.
After the 20-second warm-up period, research member 1 will
indicate the beginning of the 2-minute monitoring period by
announcing the word Start. The HCP will start their manual
counting of the participant’s RR 30 seconds after the beginning
of each new metronome rate; they will be informed by research
member 1 when to start counting. They will be given 60 seconds
to calculate the manual RR and will be informed by research
member 1 when to stop counting. They will then record the RR
in the case report form. The participant will continue to breathe
at the specified rate for a further 30 seconds (for a total of 2
minutes) and will be informed by research member 1 when the
metronome rate has finished so that they return to normal
breathing.
Figure 2. Schematic of room layout.
Research member 3, blinded to the rates being played in each
metronome rate, will record RR values for the continuous ECG
and capnography monitoring and the X Series monitor (Zoll
Medical Corp) at 60 and 120 seconds. Research member 2 will
press the Start and Stop button on the RespiraSense device at
the beginning and end of each 2-minute metronome rate and
will record the start and stop time on the case report form.
Following the 10 metronome rates, the participant will then be
asked to read a verse from a book for 2 minutes. During this
time, their RR will be monitored in the same way as for the 10
metronome rates. Once the participant has finished reading
aloud, the study will finish.
Throughout the study procedure, a video recording will be made
using the portable Scotia Medical Observation and Training
System (Scotia UK Plc), the audiovisual system installed in the
simulation suite, which includes an in situ camera system
(hardware and software).
Ethical Considerations
The study will not be initiated before the protocol and all study
relevant material such as the informed consent forms and PIS
have received approval/favorable opinion from the Health
Research Authority and PHT Research and Development
department. Any changes to protocol or relevant study
documents will be approved by the sponsor. As RespiraSense
is a CE-marked product being used within its intended purpose,
regulatory approval is not necessary for this investigation.
Study Device
The RespiraSense device is based on piezoelectric technology.
This technology is in the form of films that are an ultraflat
laminated layer of piezo material. This material, when bent or
strained, produces a small varying voltage difference. This
monitor measures the motion of the chest and abdomen during
respiratory effort to measure the RR directly from this motion.
The stages of development of these devices are described as
fully compliant devices to European Medical Device Standards.
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RespiraSense is intended to act as a short-term monitoring
device to assess RR over time by continuously recording,
storing, and periodically transmitting RR data. It has no
diagnostic function in this study.
Traceability of each device’s construction will be recorded in
the company’s Design History File. Each lobe used on a patient
will be recorded in an accountability log with the patient study
number. Sensors will not be retained once used and will be
disposed of by the patient or the HCP.
During this investigation, the sensor will be attached to the
patient’s skin in the chest area using medical grade adhesive
that has been tested to and complies with ISO10993 (Biological
evaluation of medical devices). The RespiraSense device has
the dimensions 100 mm × 55 mm × 15 mm, the sensor weighs
50 grams, and the following risks are listed:
• Class IIb medical device which conforms with
IEC60601-1:A1:2012 and so no risk of electrical shock as
no electrical current is passed through the body
• The device has low weight and as such is not considered
to produce any skin ulcers
• The device will be adhered using medical grade tape which
will minimize reaction to adhesive
• Wireless transmission of information conforms to standard
Bluetooth communication protocols which are currently
used in clinical settings
• Discomfort to the patient is considered minimum as the
device in placed in a position where side-lying will not
cause added pressure to the patient
The RespiraSense is a noninvasive, body-worn, cableless,
battery-powered, respiration rate monitoring device. The system
consists of 3 parts as shown in Figure 3: the lobe, sensor, and
software application. This figure also shows the final assembled
device attached to the patient.
Figure 3. RespiraSense device and data flow.
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The system uses a specifically designed adhesive attachment
accessory (sensor), which fixes the device to the patient’s chest
and contains piezo films that convert breathing motion into an
electrical output. The lobe provides and communicates
measurement values and technical information such as battery
state wirelessly via Bluetooth to the software application hosted
on a commercial off-the-shelf tablet computer. It can also
provide basic information on activity status of the patient. The
application and removal of the elements of the RespiraSense
device, along with the maintenance of the device during
operation, will be managed by a trained research nurse. Nasal
end-tidal CO2 monitoring will be performed using Microstream
Smart CapnoLine Plus EtCO2 sampling line (Zoll Medical Corp)
with a disposable adult/intermediate nasal cannula. Data will
be collected and automatically logged onto an SD card in the
X Series monitor.
Data Transfer and Processing
Once the participant has completed the study, all data collected
by the RespiraSense device will be uploaded to a secure
cloud-based storage system from which it will be extracted and
analyzed by the team at PMD Solutions Ltd. This data will be
anonymized and linked to a specific subject ID number allocated
during the study. No participant identifiable data will be
transmitted to the team at PMD Solutions Ltd. The
RespiraSense-calculated RRs for each participant will then be
matched to the data collected by the other methods for analysis.
The study database and video recording files will be stored on
secure Trust electronic file servers. The associated file name
storing this data will be labeled with the title of the clinical
investigation and linked to the subject ID number. This file will
be saved for a minimum duration of 5 years and will be made
available to national authorities upon request in writing. All
digital and paper archives will conform to the requirements of
the Data Protection Act (United Kingdom, 2018) which
incorporates the standards laid out by the General Data
Protection Regulation (European Union, 2016).
Statistical Analysis
The primary end point is the RR as measured by multiple
methods. The primary objective of the analysis is to examine
the agreement between the RespiraSense device and the other
measurement methods for this end point. The mean difference
between each pair of methods will be calculated with 95%
confidence intervals. Variances will be tested for nonequality
with an F test. The distributions of the differences will be
examined with Bland-Altman plots. Limits of agreement (LoAs)
and proportions of measurements outside the limits will be
compared. If the differences between methods markedly increase
with their mean, the analysis will be repeated with a log
transformation of the measurements. A secondary analysis of
agreement by participant position (45 degree sitting vs other
positions) for each pair of methods will be performed using an
analysis of variance.
Patient Population Size
We expect to have statistically significant data following the
collection of 300 data sets (10 distinct measurements taken from
30 unique participants). This is based on statistical analysis of
previous studies.
The precision of the mean and precision of the LoAs depend
on the standard deviation of the differences. We use the value
of 1.79 breaths per minute as the standard deviation reported
in the Lee study [12] for comparison of RespiraSense and ECG
and the same value for the comparison of RespiraSense with
end-tidal capnography, this being regarded as more accurate
than ECG. For comparison with an HCP, we use the value of
2.5 breaths per minute, also from the Lee study.
Table 3 shows the number required for different precisions of
the mean difference using 95% confidence intervals. Table 4
shows the number required for different precisions of the LoA.
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Table 3. Precision of mean at 95% confidence interval.
NStandard error of the meanPrecision of the meanBreaths per minute
130.5111.79
500.260.51.79
770.20.41.79
1370.150.31.79
197a0.130.251.79
3080.10.21.79
12310.050.11.79
250.5112.5
970.260.52.5
1510.20.42.5
267a0.150.32.5
3850.130.252.5
6010.10.22.5
24010.050.12.5
aPrecisions to be expected if 30 participants provide 10 data points each, allowing for a 10% loss of data.
Table 4. Precision of limits of agreement at 95% confidence interval.
NStandard error of LoAPrecision of LoAaBreaths per minute
370.5111.79
1480.260.51.79
231b0.20.41.79
4110.150.31.79
5910.130.251.79
9240.10.21.79
36930.050.11.79
730.5112.5
201b0.310.62.5
2890.260.52.5
4510.20.42.5
8010.150.32.5
11530.130.252.5
18010.10.22.5
72030.050.12.5
aLoA: limits of agreement.
bPrecisions to be expected if 30 participants provide 10 data points each, allowing for a 10% loss of data.
Feasibility Assessment
The feasibility of performing this study with data collected from
participants in a single session is based on upon previous
successful observational studies that have been performed by
the research team at PHT. These include the Using the
Inflammacheck Device to Measure the Level of Exhaled Breath
Condensate Hydrogen Peroxide in Patients With Asthma and
Chronic Obstructive Pulmonary Disease (EXHALE) pilot study
[13] and a previous study validating the RespiraSense device
in patients with a large body mass index [14].
Results
Recruitment to this study has not yet started as funding decisions
are still pending. Therefore, results are not available at this
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stage. It is anticipated that the data required could be collected
within 2 months of first recruitment to the study and data
analysis completed within 6 months of the study start date.
Discussion
Rationale for Study Design
The Evaluation of Agreement of Breathing Rates Measured by
a Novel Device, Manual Counting, and Other Techniques Used
in Clinical Practice (VENTILATE) study will test the accuracy
of the RespiraSense device at the extremes of RR. The selection
of randomized RRs from within defined categories allows these
abnormal RRs to be compared with normal RRs without
introducing variability in the participant or the HCP.
Additionally, video recording of the study procedures allows
for independent sampling and monitoring of the ability of the
HCP to manually count the RR by another HCP.
We chose to use healthy volunteers without underlying
cardiopulmonary disease. It was not deemed safe or appropriate
to use patients exhibiting extremes of RR in an observational
study of this type. It was decided that the safest way to observe
the RRs of interest for the study would be for healthy volunteers
to consciously breathe at a given rate.
There are multiple points of contact during the screening visit
to minimize the chance that participants fail to complete the
study procedures. In addition to the standard practice of
providing a PIS and allowing the participant time to consider
what will be required of them during the study, the participants
will also experience one of the higher RRs that they will be
asked to perform during the study day. We chose to do this with
the aim of reducing the number of participants who are unable
to complete all of the study procedures.
Although the risk of harm to study participants is low, further
measures will be taken to mitigate these risks. The potential
risk of feeling unwell after breathing at high or low RRs will
be mitigated by allowing participants to rest for longer than
scheduled or to stop the procedure entirely should they feel
unable to continue. A clinician will be present throughout the
study procedures and will be able to stop the study at their
discretion if they feel it is not safe or would be inappropriate to
continue.
Additionally, the randomization of the RRs selected will be
prescreened to prevent high variability between tachypnoea and
bradypnea in a short space of time. A set of rates will be
randomly generated by a custom random number generator
which is programmed to select a rate from within each of the
categories listed in the Study Design section. Each set generated
will be reviewed by a clinician involved in the study and
assessed for extreme variability and overall safety. Sets that
pass this screening will be saved and assigned randomly to
participants at the time of the study data collection. Examples
of an acceptable and unacceptable set are shown in Table 5.
Table 5. Acceptable and unacceptable respiratory rate sets.
Sixth rateFifth rateFourth rateThird rateSecond rateFirst rate
32281723106Acceptable
9a26142231a5Unacceptable
aRates with extreme variability.
Another potential risk for participants using the RespiraSense
device is the risk of reaction to the adhesive. This risk has two
parts. The first is allergic reaction to the adhesive. This risk has
been given a risk level of 2 by the PMD risk management team.
A risk level of 2 indicates the risk has been reduced as low as
possible. Although the severity of this potential risk is high, this
occurrence has not been observed by PMD in any use of the
device and has not been found in literature searches. This risk
is mitigated by excluding volunteers who are allergic to
medical-grade adhesive.
The second component is a mild reaction to the adhesive. This
has been given a risk level of 2 by the PMD risk management
team. A risk level of 2 indicates the risk has been reduced as
low as possible. This risk is of low severity (mild
reaction/discomfort) and moderate occurrence level. This risk
is mitigated by excluding volunteers based on a skin fragility
assessment. It is also possible that mild irritation that will not
require medical intervention may be experienced for patients
on oral steroids.
The procedures will be carried out in the simulation suite in the
Learning and Development department which is located within
the Resuscitation Department of PHT, and an experienced
member of the resuscitation team will always be present. If a
participant should become unwell as a result of the procedures,
they will be withdrawn from the study and assessed by clinical
team, and subsequently care will be escalated as appropriate.
The outputs of the RespiraSense sensor will not be used to assist
any clinical decision, so there are no risks associated with use
of the data collected with the device in this study.
Limitations
The primary limitation to this study is the awareness from all
participants that they are being monitored. This may alter the
behavior of the participant and subsequently influence the data
collected from them, known as the Hawthorne effect. The most
likely influence that is expected to be seen is a change in the
method of manual RR counting performed by the HCP. There
is a large degree of variability in clinical practice when counting
the RR. The awareness of being observed has the potential to
encourage those who would use a method involving a shorter
count and multiplication to employ a full count for 60 seconds.
This will reduce the accuracy of the comparison between the
RespiraSense device and current clinical practice.
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Conclusions
The VENTILATE study will provide further validation of the
use of the RespiraSense device in subjects with abnormal
respiratory rates. It will assess the device’s ability to measure
abnormal RRs and compare with multiple other techniques used
in various aspects of clinical practice. The results provided will
help to guide the usefulness of the device in clinical practice in
the future.
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